| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2000-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec07bd8272ba32bc8c503774cadada91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a49e0a1f454223ad94d94e595b0b206 |
| publicationDate |
2003-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6534050-B1 |
| titleOfInvention |
2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes |
| abstract |
A pharmaceutically acceptable salt of 2-methyl-3-butenyl-1-pyrophosphoric acid; an agent for treating lymphocytes which comprises at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof, and a hydrate thereof; Vgamma2Vdelta2 type T cells treated by the same; and a medicine containing the same specifically stimulate and proliferate the human Vgamma2Vdelta2 type T cells, and also induce and enhance an antitumor activity thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7094557-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011112054-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008249067-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003152551-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7749760-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7399756-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006030546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7871992-B2 |
| priorityDate |
1999-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |